Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY0467
- Development stage
- Phase 2
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KY0467 is an investigational oral drug developed by Jiangsu Kanion Pharmaceutical. It is currently in Phase 2 clinical development, primarily targeting infectious diseases. The precise mechanism of action for KY0467 has not been disclosed publicly, and it is not known to represent a novel mechanism of action. Clinical trials have focused on evaluating the safety and tolerability of single and multiple oral doses in healthy adults under fasting conditions[1][2][3].
Beyond the preview
Go deeper on KY0467.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KY0467.